270
Participants
Start Date
October 21, 2024
Primary Completion Date
January 31, 2029
Study Completion Date
April 30, 2029
Ulviprubart (ABC008)
All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Royal North Shore Hospital, Saint Leonards
Royal Brisbane and Women's Hospital, Herston
Perron Institute for Neurological and Translational Science, Nedlands
Hospital for Special Surgery, New York
UPMC Arthritis and Autoimmunity Center, Falk Clinic, Pittsburgh
Penn State Health Milton S. Hershey Medical Center, Hershey
University of Pennsylvania, Philadelphia
Virginia Commonwealth University, Henrico
Duke Neurological Disorders Clinic, Durham
Ohio State University Wexner Medical Center, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Medical College of Wisconsin, Milwaukee
Texas Neurology, Dallas
Nerve and Muscle Center of Texas, Houston
Austin Neuromuscular Center, Austin
Neuromuscular Research Center, Phoenix
Keck Hospital of USC, Los Angeles
University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center, Irvine
Yale School of Medicine, New Haven
Neuromuscular Diagnostic Center - Massachusetts General Hospital, Boston
Brigham and Womens Hospital, Boston
Abcuro, Inc.
INDUSTRY